Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients

Hepatology Research

Volumn 41, Issue 12, 2011, Pages 1189-1198

  Ishigami, Masatoshi ^a   Onishi, Yasuharu ^a   Ito, Takashi ^a   Katano, Yoshiaki ^a   Ito, Akihiro ^a   Hirooka, Yoshiki ^a   Kiuchi, Tetsuya ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti hepatitis B surface immunoglobulin; Cost; Early preoperative period; Hepatitis B virus; Liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE ANALOG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COST OF ILLNESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; VIRUS REACTIVATION;

EID: 82255181569     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00884.x     Document Type: Article

References (41)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related disease. Hepatology 1991; 13: 619-26.
2. Eason JD, Freeman RB Jr, Rohrer RJ etal. Should liver transplantation be performed for patients with hepatitis B? Transplantation 1994; 57: 1588-93.
3. Han SH, Ofman J, Holt C etal. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
4. Dumortier J, Chevallier P, Scoazee JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002.
5. Rosneau J, Bahr MJ, Tillmann HL etal. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
6. Markowitz JS, Martin P, Conrad AJ etal. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
7. Marzano A, Salizzoni M, Debernardi-Venon W etal. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Heaptol 2001; 34: 903-10.
8. Shouval D, Samuel D. Hepatitis B Globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-95.
9. Samuel D. The option of liver transplantation for hepatitis B: where are we? Dig Dis Sci 2009; 41S: S185-9.
10. Perrilo RP, Wrught T, Rakela J etal. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-32.
11. Zheng S, Chen Y, Liang T etal. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-8.
12. Lo CM, Cheung ST, Lai CL etal. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233: 276-81.
13. Takaki A, Yagi T, Sadamori H etal. Short-term high-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-3.
14. Wong SN, Chu CJ, Wai CT etal. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-81.
15. Buti M, Mas A, Prieto M etal. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-17.
16. Buti M, Mas A, Prieto M etal. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-4.
17. Sanchez-Fueyo A, Rimola A, Grande L etal. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus by vaccination after liver transplantation. Hepatology 2000; 31: 496-501.
18. Angelico M, Di Paolo D, Trinito MO etal. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-81.
19. Karasu Z, Ozacar T, Akarca U etal. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005; 12: 212-15.
20. Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-7.
21. Rosneau J, Hooman N, Hadem J etal. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13: 367-73.
22. Ishigami M, Kamei H, Nakamura T etal. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBc-Ab positive donors. J Gatroenterol 2011;46: 367-77.
23. Bienzle U, Gunther M, Neuhaus R etal. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-19.
24. Tahara H, Tanaka K, Ishiyama K etal. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Trasnpl Int 2009; 22: 805-13.
25. Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-9.
26. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-85.
27. Yao FY, Osorio RW, Roberts JP etal. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-6.
28. Yoshida EM, Erb SR, Partovi N etal. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.
29. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
30. McCaughan GW, Spencer J, Koorey D etal. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 6: 512-19.
31. Roche B, Feray C, Gigou M etal. HBV DNA persistence 10years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
32. Seehofer D, Rayes N, Naumann U etal. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantaiton 2001; 72: 1381-5.
33. Lo CM, Fung JTK, Lau GKK etal. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37: 36-43.
34. Gane EJ, Angus PW, Strasser S etal. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-7.
35. Jiang L, Yan L, Li B etal. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-9.
36. Karasu Z, Akyildiz M, Kilic M, Zeytunlu M, Aydin U etal. Living donor liver transplantation for hepatitis B cirrhosis. J Gasteoenterol Hepatol 2007; 22: 2124-9.
37. Hwang S, Lee SG, Ahn CS etal. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 2008; 14: 770-8.
38. Faria LC, Gigou M, Rogue-Afonso AM, Sebagh M, Roche B etal. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-9.
39. Saab S, Yeganeh M, Nguyen K etal. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-34.
40. Chun J, Kim W, Kim BG etal. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttranplant hepatitis B recurrence. Am J Transplant 2010; 10: 1658-68.
41. Han SH, Reddy KR, Keeffe EB etal. and the NIH HBV-OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011; 25: E152-62.